Transforming growth factor <img src='/image/spc_char/beta.gif' border=0> 2: A predictive marker for breast cancer
IR@NISCAIR: CSIR-NISCAIR, New Delhi - ONLINE PERIODICALS REPOSITORY (NOPR)
View Archive Info| Field | Value | |
| Creator |
Dave, Heena
Trivedi, Sunil Shah, Manoj Shukla, Shilin |
|
| Date |
2011-11-01T05:01:09Z
2011-11-01T05:01:09Z 2011-11 |
|
| Identifier |
0975-1009 (Online); 0019-5189 (Print)
http://hdl.handle.net/123456789/13006 |
|
| Description |
879-887
Dual role of TGF-<img src='/image/spc_char/beta.gif' border=0> signaling in breast tumorigenesis as an inhibitor in early stages and promoter in advanced stages has been well established and known as TGF-<img src='/image/spc_char/beta.gif' border=0> switch. However, the biological mechanisms needs to be explored. Aim of the present study was to look for the usefulness of TGF-<img src='/image/spc_char/beta.gif' border=0>2 as a predictive marker for breast cancer and to offer a better predictability to identify patients likely to benefit from antiTGF-<img src='/image/spc_char/beta.gif' border=0> strategies. Circulatory as well as transcript levels of TGF-<img src='/image/spc_char/beta.gif' border=0>2 were estimated from 118 pretherapeutic breast cancer patients using ELISA and q-PCR with ddCt method. Multifactorial analysis was performed to correlate the results to clinico-pathological prognosticators and Kaplan-Meier survival analysis with a median follow-up of 49 months was also evaluated. Circulating TGF-<img src='/image/spc_char/beta.gif' border=0>2 was similar in control and breast cancer patients. TGF-<img src='/image/spc_char/beta.gif' border=0>2 was significantly upregulated in advanced tumors compared to early tumors. An inverse correlation was observed between TGF-<img src='/image/spc_char/beta.gif' border=0>2 protein and mRNA; nevertheless both exhibited significant correlations with clinico-pathological prognosticators. Higher expression of TGF-<img src='/image/spc_char/beta.gif' border=0>2 mRNA was connected to an early relapse in advanced stage than early stage patients. It is the first report to evaluate circulatory and transcript levels exhibiting TGF-<img src='/image/spc_char/beta.gif' border=0> switch and confirming the utility of TGF-<img src='/image/spc_char/beta.gif' border=0>2 as an important predictive marker for breast cancer. |
|
| Language |
en_US
|
|
| Publisher |
NISCAIR-CSIR, India
|
|
| Rights |
<img src='http://nopr.niscair.res.in/image/cc-license-sml.png'> <a href='http://creativecommons.org/licenses/by-nc-nd/2.5/in' target='_blank'>CC Attribution-Noncommercial-No Derivative Works 2.5 India</a>
|
|
| Source |
IJEB Vol.49(11) [November 2011]
|
|
| Subject |
Breast cancer
mRNA Prognosis Serum Survival TGF-<img src='/image/spc_char/beta.gif' border=0>2 |
|
| Title |
Transforming growth factor <img src='/image/spc_char/beta.gif' border=0> 2: A predictive marker for breast cancer
|
|
| Type |
Article
|
|